Omega-3-Fatty Acids in Children With Sickle Cell Disease

ConditionSickle Cell Disease (SCD)

Trial statusNot yet recruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age5-18

SponsorUniversity of Alabama at Birmingham

About this trial

The purpose of this feasibility study is to investigate the role of a dietary supplement in modulating the gut microbiota and improving pain outcomes in children with sickle cell disease (SCD).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

current use of antibiotics except prophylactic penicillin

current use of pre-or probiotic supplements

current use of PPI therapy

pregnant or lactating females

Trial design

Design model

Single group

Treatments tested in this trial

Flaxseed
Dietary supplement
Flaxseed

Treatment groups

20 Participants

are divided into 1 treatment group

Group A: FlaxseedOther 1 intervention

Trial outcomes

Primary outcomes

Feasibility

Participants will be asked to complete electronic adherence dairies- Feasibility will be defined by more than 50% of enrolled participants eating flaxseed at least 5 days a week for the study duration

Time frame

4 weeks

Secondary outcomes

Pain

Patient reported pain outcomes will be assessed weekly with pain scores and end of the study with quality of life measures

Time frame

4 weeks

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Alabama at Birmingham

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: